Lorcaserin helps increase feelings of fullness to prevent overeating. Results from a clinical trial assessing the safety of lorcaserin and lorcaserin XR show the drug may be associated with an elevated risk of tumors, but the cause of the cancer is uncertain, regulators say. The U.S. Food and Drug Administration (FDA) issued a warning on January 14, 2020, that the prescription weight loss drug lorcaserin might be associated with an increased risk of cancer.
In a clinical trial following about 12,000 patients over five years, more patients taking lorcaserin were diagnosed with cancer compared with patients taking a placebo, according to the FDA. “At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk,” the FDA said in its warning statement. “However, we wanted to make the public aware of this potential risk.” A…
